Eli Lilly and Company (NYSE: LLY) received an upgraded rating from Daiwa America on Wednesday, moving the stock from "hold" to "strong-buy."
This action follows several other favorable ratings in preceding weeks, contributing to a consensus "Moderate Buy" rating among analysts.
The upgrade reflects generally positive sentiment for the pharmaceutical giant, with multiple analysts having recently raised their price targets for the company's stock.